Hikma Pharmaceuticals (LON:HIK) was downgraded by investment analysts at Jefferies Group to an “underperform” rating in a report issued on Wednesday. They currently have a GBX 895 ($12.14) price objective on the stock, down from their prior price objective of GBX 1,074 ($14.56). Jefferies Group’s target price suggests a potential downside of 11.40% from the company’s current price.
Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Hikma Pharmaceuticals in a research note on Friday, September 29th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 1,390 ($18.85) target price on shares of Hikma Pharmaceuticals in a research note on Thursday, November 9th. dropped their target price on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.37) to GBX 865 ($11.73) and set a “reduce” rating for the company in a research note on Friday, November 10th. Stifel Nicolaus dropped their target price on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.90) to GBX 1,000 ($13.56) and set a “hold” rating for the company in a research note on Thursday, November 9th. Finally, Numis Securities raised shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($17.63) target price for the company in a research note on Thursday, November 9th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. Hikma Pharmaceuticals has an average rating of “Hold” and an average price target of GBX 1,171 ($15.88).
Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,010.13 ($13.70) on Wednesday. Hikma Pharmaceuticals has a 1-year low of GBX 906.50 ($12.29) and a 1-year high of GBX 2,346 ($31.81). The stock has a market cap of $2,440.00 and a PE ratio of 1,980.65.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.